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Based on early evidence of in vitro neurotoxicity following exposure to serum derived
from patients with amyotrophic lateral sclerosis (ALS), several studies have attempted to
explore whether cerebrospinal fluid (CSF) obtained from people with ALS could possess
similar properties. Although initial findings proved inconclusive, it is now increasingly
recognized that ALS-CSF may exert toxicity both in vitro and in vivo. Nevertheless, the
mechanism underlying CSF-induced neurodegeneration remains unclear. This review
aims to summarize the 40-year long history of CSF toxicity studies in ALS, while
discussing the various mechanisms that have been proposed, including glutamate
excitotoxicity, proteotoxicity and oxidative stress. Furthermore, we consider the potential
implications of a toxic CSF circulatory system in the pathophysiology of ALS, and also
assess its significance in the context of current ALS research.
Keywords: amyotrophic lateral sclerosis, cerebrospinal fluid, motor neuron disease, neurodegeneration,
pathophysiology, toxicity
Abbreviations: AIDA, 1-aminoindan-1,5-dicarboxylic acid; ALS, amyotrophic lateral sclerosis; ALS-CSF, cerebrospinal fluid
obtained from people with amyotrophic lateral sclerosis; AMPA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid; BDNF, brain-derived neurotrophic factor; CHIT-1, chitotriosidase-1; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione;
CNS, central nervous system; CNTF, ciliary neurotrophic factor; CSF, cerebrospinal fluid; FGF2, fibroblast growth factor
2; FTD, frontotemporal dementia; FUS, fused in sarcoma; GLAST, glutamate aspartate transporter; GLT-1, glutamate
transporter-1; hESC, human embryonic stem cell; HNE, 4-hydroxynonenal; IGF1, insulin-like growth factor 1; IgG,
immunoglobulin G; IL-6, interleukin 6; IL-10, interleukin 10; iPSC, induced pluripotent stem cell; ISF, interstitial fluid;
MAO-B, monoamine oxidase B; mGluR, metabotropic glutamate receptor; MND, motor neuron disease; NMDA, N-methyl-
D-aspartate; NO, nitric oxide; NSC-34, mouse spinal cord-neuroblastoma hybrid cell line; NSE, neuron-specific enolase;
PDGF, platelet-derived growth factor; ROS, reactive oxygen species; SOD1, superoxide dismutase 1; TDP-43, TAR DNA-
binding protein 43; TLS, translocated in liposarcoma; TNF-α, tumor necrosis factor alpha; VEGF, vascular endothelial growth
factor.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS), also known as motor
neuron disease (MND), is a neurodegenerative condition
that is pathologically characterized by the accumulation of
ubiquitinated intracellular inclusions containing TAR DNA-
binding protein 43 (TDP-43) (Neumann et al., 2006). Clinically,
it initially manifests as focal weakness, rapidly progressing
to widespread paralysis, with the resulting impairment in
respiratory function usually being fatal. About 90% of ALS
cases are believed to be sporadic, while monogenetic causes
account for the remaining occurrences (Brown and Al-
Chalabi, 2017). To date, various mechanisms such as glutamate
excitotoxicity, impaired proteostasis and dysregulation of RNA
metabolism have been implicated in ALS pathophysiology, with
neurodegeneration believed to arise from their highly complex
interplay (Hardiman et al., 2017).
EARLY SUGGESTIONS OF A
CIRCULATING TOXIN
Although the pathophysiology of ALS was comparatively little
understood in the 1970s, it had nevertheless already been
recognized as a fatal neurodegenerative disease involving the
selective loss of motor neurons (Wolfgram and Myers, 1973).
Amongst various proposed explanations for the etiology of ALS
was the existence of a circulating toxin—one thought to be
particularly hostile toward motor neurons. Based on this premise,
in vitro experiments were conducted, in which anterior horn cells
were exposed to diluted serum from ALS patients (Wolfgram and
Myers, 1973). Two important observations emerged from this
study. First, ALS serum was considerably more toxic to anterior
horn cells compared to serum obtained from patients with other
neurodegenerative diseases. Second, the observed toxicity did not
appear to extend to non-neuronal cells. The inability of the toxic
factor to undergo dialysis prompted the authors to suggest the
possibility of it being a protein, a particularly interesting proposal
given that ALS was at the time not known to be a proteinopathy.
The authors further noted a lack of association between patient
demographics and serum toxicity.
Given the potential promise of these results in explaining the
pathogenesis of ALS, subsequent experiments employing a range
of culture systems, including motor neurons and neuroblastoma
cells, were performed in the 1970s, in an attempt to reproduce
previous findings (Horwich et al., 1974; Liveson et al., 1975;
Lehrich and Couture, 1978; Viktorov and Bunina, 1979). These,
however, failed to demonstrate evidence of serum toxicity in
ALS, and it was only almost a decade later that findings of ALS
serum toxicity were successfully replicated (Roisen et al., 1982).
Intriguingly, the study investigators also observed increased
neurotoxicity following exposure to serum from the relatives of
ALS patients as well as from a number of neurological controls,
suggesting that serum toxicity was not restricted to the ALS
phenotype. In addition to confirming the specific toxicity of ALS
serum toward anterior horn cells, the authors further concluded
that the toxic factor was both non-dialysable and heat-labile.
Other studies have also investigated the effect of ALS serum on
various enzymatic reactions, with mixed results (Touzeau and
Kato, 1983, 1986; Doherty et al., 1986; Maher et al., 1987; Van
der Neut et al., 1991).
FROM SERUM TO CEREBROSPINAL
FLUID
Cerebrospinal fluid (CSF), which is often considered as an
ultrafiltrate of plasma, is a clear colorless liquid that surrounds
most of the central nervous system (CNS). In addition to
providing buoyant support and protection to the brain, it also
serves a regulatory role, made possible by substantial exchange
of material between CSF and interstitial fluid (ISF). In view of
the close proximity of CSF to neuronal cells, it was hypothesized
that the toxin could also be present in the CSF circulation. The
first study to assess the toxicity of ALS-CSF thus emerged in
1981 (Askanas et al., 1981). Measuring the levels of neuron-
specific enolase (NSE), a marker of living neurons, in neuronal
cultures treated with CSF obtained from ALS patients, however,
revealed no significant toxicity. Two subsequent studies were also
unable to demonstrate strong evidence of cytotoxicity following
exposure to ALS-CSF, although a qualitative decrease in neuronal
survival was observed in one study when exposure time was
increased (Silani et al., 1987; Swift et al., 1988). Initial evidence of
ALS-CSF toxicity arose only in 1993, with the observed toxicity
found to be dependent on CSF concentration (Couratier et al.,
1993). While additional studies were performed in the same
decade (Iwasaki et al., 1995; Gredal et al., 1996; Terro et al., 1996;
Smith et al., 1998), it could be argued that evidence for ALS-CSF
toxicity remained mostly mixed, similar to serum toxicity.
From 2000 onward, however, evidence grew strongly in
favor of the neurotoxic properties of ALS-CSF (see Table 2 in
Ng Kee Kwong et al., 2020a). This was despite heterogenous
study conditions, including different culture models, CSF
concentrations and exposure times (see Table 1 in Ng Kee Kwong
et al., 2020a). Notable was the finding that CSF from patients with
both sporadic and familial forms of ALS caused cytotoxicity when
incubated with neurons in culture. Although these results were
predominantly based on rat neuron cultures, as well as the NSC-
34 cell line (a mouse spinal cord-neuroblastoma hybrid cell line),
recent evidence involving motor neurons derived from human
induced pluripotent stem cells (iPSCs) and human embryonic
stem cells (hESCs), indicates that CSF-mediated toxicity may also
be common to human neurons (Sumitha et al., 2019; Brauer et al.,
2020). Complementing in vitro evidence, several in vivo studies
have also been performed, demonstrating a range of pathological
changes upon CSF injection. In the following sections, we
elaborate on the various in vitro and in vivo observations, and
discuss the potential underlying mechanisms (Figure 1).
EVIDENCE OF EXCITOTOXIC
MECHANISMS
Glutamate excitotoxicity has been subject to longstanding
interest in ALS research, and several studies have attempted to
assess its contribution to CSF toxicity. Early suggestions of the
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FIGURE 1 | Timeline summarizing the key events from 40 years of CSF toxicity research in ALS. Following evidence of serum toxicity in ALS in the early 1970s,
several studies started to explore the potential toxicity of ALS-CSF. By 1995, findings of CSF toxicity had been reported both in vitro and in vivo, although results
were initially inconclusive. Subsequently, however, different mechanisms such as glutamate excitotoxicity, proteotoxicity and oxidative stress became implicated in
CSF-mediated neurodegeneration, with a glial cell contribution also being demonstrated. Concurrently documented were various downstream pathological features,
including ultrastructural, as well as musculoskeletal, changes. More recently, the toxicity of ALS-CSF has been found to extend to both hESC-derived and human
iPSC-derived motor neurons.
possible involvement of excitotoxic mechanisms include the
finding that 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX),
an antagonist of the alpha-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA)/kainite receptor, could
protect against CSF-induced neurodegeneration (Couratier
et al., 1993). Although the same study failed to demonstrate
neuroprotection via blocking of N-methyl-D-aspartate (NMDA)
receptors (Couratier et al., 1993), results from other groups
suggest that both NMDA receptors and AMPA/kainate receptors
may be implicated in CSF-induced neurodegeneration (Tikka
et al., 2002; Sen et al., 2005). It was further shown that CSF-
mediated neurodegeneration was preceded by an increase in
intracellular calcium levels, with the rise being more prominent
in motor neurons compared to other spinal neurons (Sen
et al., 2005). Thus, glutamate receptor activation appears
to be much more pronounced in neurons treated with
ALS-CSF, with the variation across studies possibly arising
from differences in glutamate receptor composition amongst
employed neuronal cultures.
Concomitant experiments assessing glutamate levels in ALS-
CSF as well as glutamate receptor activation following exposure
to ALS-CSF have produced mixed evidence, with suggestions that
elevated glutamate levels may be a feature of only a subgroup
of ALS patients (Spreux-Varoquaux et al., 2002; Fiszman et al.,
2010). Whether significantly raised glutamate levels are necessary
to promote excitotoxicity is also unclear. In one study, the
approximately threefold increase in glutamate levels observed
in ALS patients was found to be sufficient to induce apoptosis
and reduce viability in CSF-exposed cells (Cid et al., 2003). In
another study, although ALS-CSF contained higher glutamate
levels, and could promote neurotoxicity via ionotropic glutamate
receptors, increased glutamate concentrations did not correlate
with the degree of induced neurotoxicity (Fiszman et al., 2010).
Conflicting findings were also reported by a different group,
in which ALS-CSF was still shown to trigger excitotoxicity, as
suggested by the protective effect of AMPA/kainate receptor
antagonists, despite glutamate levels not being significantly
elevated (Tikka et al., 2002).
Although it appears that glutamate excitotoxicity may form
part of the overall neurodegenerative pathway, suggestions
that elevated glutamate levels could be a driver of CSF-
mediated neurodegeneration are not supported by other lines
of evidence. First, neurodegeneration secondary to ALS-CSF
exposure could not be reproduced by administration of L-
glutamate in in vitro experiments (Anneser et al., 2006). Second,
more recent results show that glutamate levels considerably
higher than those found in ALS-CSF are required to produce
neurotoxicity (Yanez et al., 2011). It is also worth noting that
early findings demonstrating a possible neuroprotective effect by
riluzole (Couratier et al., 1994), which remains the only globally
licensed drug for ALS, could not be replicated (Yanez et al.,
2011). Instead, the observed neurotoxicity could be inhibited by
resveratrol, a natural antioxidant found in grapes, possibly by
suppressing elevation of cytosolic calcium levels (Yanez et al.,
2011). Other compounds found to reduce ALS-CSF toxicity
include memantine, minocycline and lithium (Yanez et al., 2014).
Intriguingly, the influence of all four neuroprotective factors
appeared to be counteracted by the presence of riluzole. While the
mechanistic underpinnings of these findings remain unclear, with
riluzole potentially exerting both neuroprotective and neurotoxic
influences in ALS, the authors suggest a possible confounding
effect from riluzole in ALS clinical trials (Yanez et al., 2014).
Lastly, we note that dialysis experiments, from which additional
insights into the contribution of glutamate to CSF toxicity could
potentially arise from, remain sparsely evidenced.
GLIAL CONTRIBUTIONS TO
CSF-MEDIATED NEURODEGENERATION
In line with the increasingly acknowledged role of astrocytes and
microglia in ALS pathophysiology (Philips and Rothstein, 2014;
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Zhao et al., 2019; Clarke and Patani, 2020; Franklin et al.,
2020), CSF toxicity has also been argued to possess a cell
non-autonomous component. Suggestive findings arose as early
as 1987 when in vitro experiments showed that ALS-CSF
exposure triggered an increase in GFAP-positive cells, consistent
with astrocyte proliferation (Silani et al., 1987). The cause of
astrogliosis is unclear, although further results showed that it
could follow from stimulation of mGluRs in response to ALS-
CSF exposure, as suggested by the anti-proliferative effect of
the mGluR group I antagonist, 1-aminoindan-1,5-dicarboxylic
acid (AIDA) (Anneser et al., 2004). Complementing in vitro
observations, ALS-CSF has also been found to promote increased
GFAP immunoreactivity when injected in rats (Shahani et al.,
1998). This time, the resulting astrogliosis was shown to be
reduced by administration of the immunosuppressive agent,
cyclophosphamide, or the selective monoamine oxidase B
(MAO-B) inhibitor, (-)-deprenyl (Shahani et al., 2001, 2004).
Nevertheless, given that a proportion of astrocytes may only
become GFAP-positive following insult (Sofroniew and Vinters,
2010), increases in GFAP-positive cells could potentially be
independent of astrocyte proliferation.
As the possible involvement of astrocytes further prompted
researchers to investigate their role in glutamate excitotoxicity,
one of the emergent findings was downregulation of the
expression of glutamate transporter-1 (GLT-1/SLC1A2/EAAT2),
which is expressed by astrocytes and is involved in glutamate
uptake, following exposure to ALS-CSF (Shobha et al., 2007).
Various mechanisms, such as abnormal mRNA processing and
lipid peroxidation, have been proposed for the decreased GLT-
1 expression. Expression of glutamate aspartate transporter
(GLAST/SLC1A3/EAAT1) was, however, not found to be
affected. More recent evidence showed that the reduction in
glutamate uptake was also accompanied by a significant increase
in the release of glutamate (Mishra et al., 2016). Nevertheless,
whether the raised extracellular glutamate levels resulting from
reduced glutamate uptake could contribute to neuronal death
is still unclear.
Early findings have also implicated microglia in CSF-mediated
neurodegeneration. Upon administration of minocycline, which
blocks microglial activation, a neuroprotective effect was
observed following CSF exposure (Tikka et al., 2002). Given that
antagonists of NMDA receptors and AMPA/kainate receptors
could also suppress the observed neurotoxicity, but without
influencing microglial activation, the authors proposed that
ALS-CSF may contain toxic factors that promote microglial
activation, which, in turn, leads to the activation of ionotropic
glutamate receptors and neuronal death. Nevertheless, the
variable proportion of astrocytes and microglia across studies,
which could range from five percent to thirty percent glial
constitution, makes their exact contribution to CSF-induced
neurodegeneration difficult to establish (Couratier et al., 1993;
Tikka et al., 2002). In one study where microglia made up
less than one percent of the total cell count for instance,
neurodegeneration via a glutamate-dependent pathway could
still be observed (Anneser et al., 2006).
The pro-inflammatory properties of ALS-CSF are further
highlighted by its ability to upregulate in astrocytes the expression
of various inflammatory factors, including interleukin 6 (IL-6)
and tumor necrosis factor alpha (TNF-α), while increasing
production of nitric oxide (NO) and reactive oxygen species
(ROS) (Mishra et al., 2016). Expression of anti-inflammatory
cytokines such as interleukin 10 (IL-10) was also found to be
downregulated. The possible contribution of these changes
to a neurotoxic environment is supported by the finding that
conditioned medium from CSF-exposed astrocytes could
promote neurodegeneration (Mishra et al., 2016). Similar
observations have been made regarding microglia, with
changes in the expression levels of both pro-inflammatory
and anti-inflammatory cytokines, along with increased
toxicity of microglia-conditioned medium toward neurons
(Mishra et al., 2017).
Although many potentially toxic factors have emerged from
studying the effects of ALS-CSF on glial cells, chitotriosidase-
1 (CHIT-1), an inflammatory product specific to microglia, has
been proposed to play a particularly important role in CSF-
mediated neurodegeneration (Varghese et al., 2020). Proteomic
analysis found CHIT-1 to be significantly upregulated in ALS-
CSF compared to control CSF, suggesting its possible role as
a biomarker (Varghese et al., 2013). This was subsequently
substantiated by findings from the same group demonstrating
its high specificity and sensitivity as a diagnostic biomarker
(Varghese et al., 2020). It is worth commenting that the
function of CHIT-1 in the human nervous system has still not
been established, with CHIT-1 also being implicated in other
neurodegenerative diseases, such as Alzheimer’s disease and
multiple sclerosis (Varghese et al., 2020). Notwithstanding this,
the particularly elevated levels of CHIT-1 in ALS-CSF, which have
been found to promote astrogliosis and microgliosis, as well as
neuronal loss, support its possible participation in CSF-mediated
neurodegeneration (Varghese et al., 2020).
There are also intriguing observations derived from co-culture
studies that suggest that the glial influence may be more complex
than a direct contribution to neuronal loss. Although exposure of
motor neuron mono-cultures to both ALS-CSF and control-CSF
resulted in neuronal death, motor neurons co-cultured with glia
experienced no significant decrease in survival following ALS-
CSF exposure, with administration of control-CSF even leading
to an increase in cell count (Barber et al., 2011). As well as
emphasizing the role of glia in CSF-mediated neurodegeneration,
these findings, as the authors proposed, suggest the presence of
factors that may have a neuroprotective effect, in addition to toxic
components in CSF.
ALS AS A PROTEINOPATHY
While ALS is now recognized as a proteinopathy, proteotoxicity
initially received comparatively little attention as a possible
underlying mechanism in both ALS pathophysiology and CSF-
mediated neurodegeneration. In fact, it was found that CSF
toxicity could neither be suppressed by prior heating nor by using
a 5 kDa filter, thus appearing to exclude the possibility of the
toxic agent being a protein (Anneser et al., 2006). Much more
recent evidence, however, supports the involvement of key ALS
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proteins, including superoxide dismutase 1 (SOD1) and TDP-
43. Although CSF concentrations of SOD1 in ALS patients are
not known to be significantly different from other individuals
(Zetterstrom et al., 2011; Winer et al., 2013), misfolded SOD1
present in CSF obtained from patients with sporadic ALS has
been shown to be highly toxic to NSC-34 cells, with antibody-
mediated depletion to remove the misfolded SOD1 found
to produce a significant reduction in neurotoxicity (Tokuda
et al., 2019). Whether misfolding of the SOD1 protein is a
phenomenon occurring inside cells or within the CSF circulation,
as well as the factors promoting its occurrence, remain, however,
incompletely understood.
With TDP-43 known to be present in ALS-CSF (Majumder
et al., 2018), several attempts have also been made to establish
the impact of ALS-CSF exposure on TDP-43 aggregation, and
the associated downstream features. Intraventricular injection
of CSF from ALS patients into rats resulted in the formation
of cytosolic inclusions of TDP-43 co-localizing with ubiquitin
(Gomez-Pinedo et al., 2018). In a later study, ALS-CSF injection
was also found to induce TDP-43 proteinopathy as well as
motor and cognitive disability in hTDP43 mice (Mishra et al.,
2020). TDP-43 proteinopathy was, however, not observed in
normal mice, although mild motor deficits were described.
The authors further noted increased vulnerability with age,
with 8-month-old mice experiencing a greater degree of
muscle impairment when compared to younger mice. Earlier
in vitro findings of TDP-43 mislocalization were again observed
following ALS-CSF exposure, a feature which has previously been
shown to be partially reversed by vascular endothelial growth
factor (VEGF) supplementation (Shantanu et al., 2017). Other
intriguing findings to emerge from the same study were the
mislocalization of fused in sarcoma/translocated in liposarcoma
(FUS/TLS) and formation of stress granules secondary to
ALS-CSF exposure, with reversibility by VEGF further being
demonstrated (Shantanu et al., 2017).
A more recent study employing human iPSC-derived motor
neurons, however, failed to observe such changes following ALS-
CSF exposure (Brauer et al., 2020). Additionally, although CSF
exposure produced significant neuronal loss, this effect did not
appear to be specific to cells treated with ALS-CSF. Nevertheless,
exposure to ALS-CSF resulted in significantly higher Golgi
fragmentation rates, possibly suggestive of an early sign of
neurodegeneration. It has therefore been suggested that a dose-
dependent effect may underlie the induction of pathological
changes in cells (Brauer et al., 2020; Mishra et al., 2020).
In support of this is the finding that TDP-43 mislocalisation
and aggregation could be observed only when human glioma
U251 cells were exposed to CSF from patients with both ALS
and frontotemporal dementia (FTD), while CSF from ALS
and control patients failed to induce similar pathology (Ding
et al., 2015), consistent with the greater TDP-43 pathology
seen in ALS-FTD.
Although additional evidence is required to establish the
contribution of TDP-43 and SOD1 to the neurotoxicity of
ALS-CSF, these findings could have important implications in
our understanding of ALS pathophysiology. Of note is the
possibility already suggested by others that the CSF circulation
could constitute a pathway for the spread of pathology, which
various lines of evidence are now hinting at (Smith et al.,
2015; Gomez-Pinedo et al., 2018; Mishra et al., 2020). This
could in turn help to potentially account for many of the
unexplained features of ALS, one of which is the non-contiguous
spreading pattern occasionally observed (Smith et al., 2015;
Ng Kee Kwong et al., 2020b).
OTHER POTENTIAL CANDIDATES
Beyond the different factors already described, other components
of ALS-CSF could also be responsible for its toxicity toward
cells. Levels of 4-hydroxynonenal (HNE), a marker of lipid
peroxidation, when raised to that of ALS-CSF, have been
found to induce neuronal loss in vitro (Smith et al., 1998).
Potentially elevated concentrations of 3-nitrotyrosine, as
seen in patients with sporadic ALS, could also indicate
oxidative stress by peroxynitrite, which has been shown to
activate astrocytes and promote neurodegeneration (Tohgi
et al., 1999; Cassina et al., 2002). While the contribution
of oxidative stress as an underlying mechanism for CSF-
mediated neurodegeneration remains unclear, with definite
conclusions from studies measuring levels of oxidative stress
biomarkers in ALS-CSF not being possible, antioxidants such
as allopurinol and vitamin E have been found to suppress
in vitro neurotoxicity following exposure to ALS-CSF (Terro
et al., 1996). In addition to the various inflammatory cytokines
with potentially neurotoxic properties, such as IL-6 and TNF-α
(Moreau et al., 2005), immunoglobulin G (IgG) from ALS
patients could be yet another contributing factor to CSF
toxicity, given their previously evidenced role in promoting
neurodegeneration and microgliosis (Obal et al., 2001; Pullen
et al., 2004; Demestre et al., 2005). Finally, the possibility that
accumulation of other metabolic waste products could result in




Several pathological changes have been observed across
both in vitro and in vivo models in response to ALS-CSF
administration. During the 1990s, increased neurofilament
phosphorylation was reported when chick spinal cord neurons
were exposed to ALS-CSF (Nagaraja et al., 1994), a finding
subsequently reproduced in vivo, with the change being
considerably more pronounced in ventral horn motor neurons
(Rao et al., 1995). Despite being repeatedly linked to ALS-CSF
exposure, the cause of neurofilament phosphorylation, as well
as its contribution to CSF-mediated neurodegeneration, is still
poorly understood (Vijayalakshmi et al., 2009). Ultrastructural
changes following exposure to ALS-CSF also include Golgi
fragmentation and endoplasmic reticulum stress, the latter being
supported by free polyribosomes and fragmented ER cisternae
being observed microscopically (Ramamohan et al., 2007;
Frontiers in Molecular Neuroscience | www.frontiersin.org 5 March 2021 | Volume 14 | Article 647895
fnmol-14-647895 March 13, 2021 Time: 16:23 # 6
Ng Kee Kwong et al. CSF Toxicity in ALS Pathophysiology
Vijayalakshmi et al., 2011; Brauer et al., 2020). Mitochondrial
and lysosomal dysregulation have also been described,
hinting at possible oxidative stress (Sharma et al., 2016).
While apoptosis is another downstream feature of ALS-CSF
exposure (Vijayalakshmi et al., 2011), it is again unclear
whether this could be a direct consequence of the various
ultrastructural observations.
In addition to cellular changes, intrathecal and
intraventricular infusion of ALS-CSF in rat models were also
found to result in motor impairment and other musculoskeletal
features (Sankaranarayani et al., 2010, 2014; Sumitha et al., 2014;
Shanmukha et al., 2018). These could possibly be attributed to
altered neuronal activity in the motor cortex, in which increased
neuronal excitability was observed (Sankaranarayani et al.,
2010, 2014; Shanmukha et al., 2018). It has previously been
shown that ALS-CSF exposure could lead to reduced expression
levels of ion channels, including Nav1.6 and Kv1.6 channels
(Gunasekaran et al., 2009), although their exact association
with motor changes is yet to be explored. The expression
of miR-206, which is involved in muscle development, was
also found to be altered by ALS-CSF infusion (Sumitha et al.,
2014). A more recent study reported significant damage to
the neuromuscular junction following intrathecal injection of
ALS-CSF, along with mitochondrial and sarcoplasmic reticular
defects (Shanmukha et al., 2018). The cellular changes produced
by intrathecal administration of ALS-CSF have also been found
to reflect the degree of motor impairment (Das et al., 2020).
Overall, these findings suggest that mechanisms common to both




Intriguingly, several neuroprotective factors have also emerged
from CSF toxicity studies. VEGF, which has previously been
implicated in ALS pathophysiology (Oosthuyse et al., 2001;
Lambrechts et al., 2003; Azzouz et al., 2004; Storkebaum et al.,
2005), has also been shown to counteract the neurotoxicity
of ALS-CSF, reversing morphological changes and decreasing
aggregation of phosphorylated neurofilaments (Kulshreshtha
et al., 2011). In a later study, VEGF supplementation was further
found to reduce caspase-3 levels and restore the expression
of calbindin-D28K expression following ALS-CSF exposure,
the latter possibly contributing to improved calcium buffering
capacity (Vijayalakshmi et al., 2015). It is also worth pointing out
that the expression of various growth factors, including brain-
derived neurotrophic factor (BDNF), fibroblast growth factor 2
(FGF2) and insulin-like growth factor 1 (IGF1), is downregulated
upon ALS-CSF infusion (Deepa et al., 2011). While the exact
downstream consequences remain unclear, administration of
BDNF, ciliary neurotrophic factor (CNTF) and platelet-derived
growth factor (PDGF) has been shown to offer neuroprotection
(Gunasekaran et al., 2009; Deepa et al., 2011; Chen et al., 2014;
Shruthi et al., 2017).
IS THERE A CONSENSUS REGARDING
CSF TOXICITY IN ALS?
Despite the increasing recognition that ALS-CSF may promote
neurodegeneration, with various studies having attempted to
characterize its toxicity, synthesizing the current body of
literature remains challenging (Box 1). Most prominently,
substantial heterogeneity exists across studies with regard to
the employed disease models and CSF exposure conditions
(Ng Kee Kwong et al., 2020a). For instance, many studies
have been performed using rat culture systems and NSC-
34 cells, although results have recently been reproduced
in human iPSC-derived and hESC-derived motor neurons
(Sumitha et al., 2019; Brauer et al., 2020). We have also
previously described considerable variation in how results
are reported and interpreted across studies (Ng Kee Kwong
et al., 2020a). Additionally, different patient and control
populations are often recruited, the latter including subjects
with wide-ranging conditions which could influence their CSF
composition. However, we acknowledge the ethical implications
of obtaining CSF from healthy controls. Along this line, it
is also often not feasible to recruit larger patient populations
in such studies.
It is still unclear why conflicting findings have been
obtained in early toxicity studies, both in those involving
serum and CSF. Studies concomitantly investigating the toxicity
of serum and CSF in ALS patients have, to our knowledge,
not been conducted, and could potentially reveal additional
insights into their association. Furthermore, no significant
correlation has to date been observed by studies assessing the
possible relationship between CSF toxicity and demographic
and clinical variables, suggesting that CSF toxicity may
not represent a possible biomarker for disease stratification
(Tikka et al., 2002; Anneser et al., 2006; Barber et al.,
2011; Yanez et al., 2011; Galan et al., 2017). Although the
underlying reasons for this lack of association deserve further
investigation, they could nonetheless help to confirm the
nature of ALS as a highly heterogeneous disease. This would,
notwithstanding methodological considerations, be consistent
with recent evidence demonstrating that CSF cytotoxicity is not a
feature of all ALS patients (Galan et al., 2017).
In spite of this, there are a number of advantages to
considering the neurotoxicity of CSF in an ALS model. First,
BOX 1 | Outstanding questions regarding CSF toxicity in ALS.
• What is the nature of the circulating toxin responsible for CSF-induced
neurodegeneration?
• What is the cellular origin of this circulating toxin?
• What is/are the mechanism/s by which it triggers neurodegeneration?
• Do astrocytes and microglia play a role in mediating CSF toxicity?
• To what extent does CSF composition reflect that of ISF?
• What is the contribution of CSF toxicity toward ALS pathophysiology?
• How accurately do the models employed to study CSF toxicity
recapitulate human in vivo conditions?
• Could similar mechanisms explain CSF toxicity in sporadic and familial
forms of ALS?
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FIGURE 2 | Summary of current understanding of CSF toxicity in ALS. While the exact cause of CSF-induced neurodegeneration remains to be established, various
mechanisms of neurotoxicity have been evidenced, and could potentially be attributed to several candidate factors, of which some may not yet be known. The
neuroprotective qualities of certain growth factors, glutamate receptor antagonists and antioxidants have also been demonstrated in vitro, although the contribution
of protective factors in in vivo models is still unclear. Nevertheless, the existing literature suggests that a highly complex interplay may exist between ALS-CSF, glial
cells and neurons, with the involvement of both toxic and protective factors that could directly or indirectly influence neuronal degeneration.
CSF toxicity, which has been observed across both sporadic
and familial forms of ALS, could potentially form part of a
common pathogenic pathway in ALS, thus helping to reconcile
the two forms of ALS. Although its contribution in ALS
pathophysiology has not yet been established, ALS-CSF toxicity
appears to possess many common features, including an apparent
predilection for motor neurons and an important cell non-
autonomous component. As previously mentioned, the presence
of a circulating toxin in CSF could also offer possible explanations
for the spread of pathology in ALS (Smith et al., 2015).
Future research may benefit from additional insights into the
cellular origin of this circulating toxin, which has remained
elusive to date. The possibility that toxicity may be a feature
acquired within the CSF circulation, as has been proposed in
the case of SOD1 misfolding (Tokuda et al., 2019), however,
cannot be excluded.
While drawing definite conclusions at this stage may
not be possible, we believe, based on the numerous
observations derived from past studies, that ALS-CSF
contains both toxic and protective factors, and is able to
promote neurodegeneration either directly or indirectly
via a process mediated by both astrocytes and microglia
(Figure 2). The neurodegenerative process may be driven by
proteotoxicity or neuroinflammation, with possible contribution
from other toxic components of CSF. Although evidence
suggests that endogenous glutamate is unlikely to initiate the
neurodegenerative process, glutamate excitotoxicity is likely to
be an important step in the overall pathway. Other downstream
consequences leading to the death of motor neurons may include
Golgi fragmentation, mitochondrial dysfunction, oxidative
stress and apoptosis.
Additional studies are nevertheless required to improve our
understanding of CSF toxicity based on both its constitution
and dynamics. Although proteomic and lipidomic studies have
revealed altered levels of inflammatory markers as well as a
different lipid profile in ALS-CSF (Barschke et al., 2017; Blasco
et al., 2017; Hayashi et al., 2019), the literature surrounding
proteomics in the study of CSF toxicity remains sparse (Varghese
et al., 2013), despite its potential in revealing additional
candidates for the toxicity of ALS-CSF. CSF biomarker studies
have shown many ALS-associated proteins, including TDP-43
and neurofilaments, to be significantly elevated in ALS-CSF
(Schreiber et al., 2018; Kasai et al., 2019). While it is unclear
whether this may be due to increased production or reduced
clearance, the contribution of CSF in their regulation may
deserve investigation. Given the currently limited understanding
of CSF dynamics, we also propose that investigating the interplay
between the extracellular space and the CSF circulation, in which
the glymphatic system has been shown to play an important
role (Jessen et al., 2015; Plog and Nedergaard, 2018), may help
to establish how accurately CSF constitution reflects that of
the interstitium. Ependymal cells and astrocytes, which are in
direct contact with the CSF, could potentially be vulnerable
to its toxicity in ALS patients. Finally, we posit, based on
recent evidence of CSF-mediated neurodegeneration in multiple
sclerosis and Parkinson’s disease (Kong et al., 2015; Wentling
et al., 2019), that CSF toxicity may well be a feature of
other neurodegenerative diseases, thus adding to the growing
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list of common mechanisms that appear to underpin their
pathophysiology.
CONCLUSION
From initial findings of serum toxicity to current in vivo and
in vitro evidence of CSF toxicity, striking similarities have been
observed between CSF-mediated neurodegeneration and ALS
pathophysiology. Although it would be difficult at this stage to
argue for the role CSF toxicity as a driver of the disease process,
we believe that the potential promise of CSF toxicity in capturing
the broader pathophysiological picture of ALS may warrant its
additional attention as an area of active research.
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